金迪克11月26日发布公告，公司股票连续2个交易日内（2025年11月25日､2025年11月26日）收盘价格涨 幅偏离值累计达到30%，根据有关规定，属于股票交易异常波动情形。经核实，目前生产经营活动一切 正常，公司所处市场环境､行业政策没有发生重大调整；生产成本和销售等情况没有出现大幅波动；近 期未签订或正在磋商重大合同；无为产业转型升级投资新项目的情形。公司及控股股东、实际控制人不 存在应披露未披露的重大信息，包括但不限于正在筹划的并购重组、股份发行、债务重组、业务重组、 资产剥离和资产注入等重大事项。 ...

金迪克公告称，公司股票在2025年11月25日、26日收盘价格涨幅偏离值累计达30%，属异常波动。经自 查，公司及实控人无应披露未披露重大信息，生产经营正常。2025年前三季度，公司营收7465.76万 元，同比增91.93%，净利润-8647.06万元，扣非净利润-9111.37万元，预计全年或无法盈利。本年度生 产季结束，四价流感疫苗批签发约156万支，销售有不确定性，且可能有退货情况。公司提醒投资者注 意交易风险。 ...

资金面上，金迪克上一交易日主力资金净流入3747.57万元，近5日净流入30.75万元。 融资融券数据显示，该股最新（11月25日）两融余额为3509.00万元，其中，融资余额为3509.00万元， 较上一个交易日减少612.53万元，降幅为14.86%；近10日两融余额合计减少150.85万元，降幅为 4.12%，其间融资余额下降4.12%。（数据宝） （文章来源：证券时报网） 11月26日盘中科创板股金迪克涨停，截至10:17，股价报30.90元，成交4.08亿元，换手率11.18%，振幅 15.61%。 科创板个股中，截至发稿上涨的共有431只，涨幅在10%以上的共有7只，涨幅较高的有明微电子、金迪 克、前沿生物-U等，分别上涨20.01%、20.00%、18.99%，下跌的有149只，跌幅较大的有佳驰科技、禾 信仪器、国科军工，分别下跌7.14%、6.30%、5.65%。 ...

欧林生物11月26日早间公告，公司于2025年11月25日向香港联交所递交了境外公开发行股份（H股）并 在香港联交所主板上市的申请，并于同日在香港联交所网站刊登了本次发行上市的申请资料。 ...

智通财经APP讯，欧林生物(688319.SH)发布公告，公司于2025年11月25日向香港联合交易所有限公司 (以下简称"香港联交所")递交了境外公开发行股份(H股)并在香港联交所主板上市的申请，并于同日在香 港联交所网站刊登了本次发行上市的申请资料。 ...

两融数据显示，该股最新融资余额为6.30亿元，近5日减少3892.49万元，降幅为5.82%。（数据宝） 11月25日微芯生物大宗交易一览 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | | | | 股） | | （元） | | | | | 30.00 | 726.00 | 24.20 | -11.68 | 机构专用 | 国投证券股份有限公司深圳 | | | | | | | 宝安海秀路证券营业部 | | 10.00 | 242.00 | 24.20 | -11.68 | 华宝证券股份有限公司 | 国投证券股份有限公司深圳 | | | | | | 合肥潜山路证券营业部 | 宝安海秀路证券营业部 | | 8.30 | 200.86 | 24.20 | -11.68 | 中信证券股份有限公司 | 国投证券股份有限公司深圳 | | | | | | 上海分公司 | 宝安海秀路证券营业部 | | 8.30 | 200.86 | 24.20 | -11 ...

Group 1 - The core viewpoint of the article highlights that Anke Bio (SZ 300009) held its 24th meeting of the 8th Board of Directors on November 24, 2025, to discuss the proposal for the third extraordinary general meeting of shareholders in 2025 [1] - For the first half of 2025, Anke Bio's revenue composition is as follows: 73.51% from genetic engineering drugs, 16.77% from other businesses, and 9.72% from external patches [1] - As of the report date, Anke Bio's market capitalization stands at 16.6 billion yuan [1] Group 2 - The article also mentions that a company identified by the code 688496 is under investigation by the China Securities Regulatory Commission (CSRC) due to a significant loss exceeding 100 million yuan shortly after its IPO, with its main customer reducing purchases by using its own production [1]

Market Overview - The biopharmaceutical sector increased by 0.83% on November 25, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Biopharmaceutical Sector - Jinke (688670) closed at 25.75, up 19.99% with a trading volume of 92,200 shares [1] - Hualan Biological (301207) closed at 23.33, up 11.25% with a trading volume of 250,500 shares [1] - Saiseng Pharmaceutical (300485) closed at 11.95, up 5.19% with a trading volume of 168,000 shares [1] - Other notable gainers include Bohui Innovation (300318) at 6.84 (+3.32%) and Dongbao Biological (300239) at 5.72 (+3.25%) [1] Market Capital Flow - The biopharmaceutical sector saw a net inflow of 40.88 million yuan from institutional investors, while retail investors experienced a net outflow of 147 million yuan [2] - The sector's overall capital flow indicates a strong interest from institutional investors despite retail selling pressure [2] Individual Stock Capital Flow - Jinke (688670) had a net inflow of 39.66 million yuan from institutional investors, while retail investors showed a net outflow of 13.72 million yuan [3] - Other stocks like Watson Bio (300142) and Hualan Bio (002007) also experienced significant net inflows from institutional investors, indicating positive sentiment [3] - Conversely, stocks like Dongbao Biological (300239) and Bohui Innovation (300318) faced net outflows from retail investors, suggesting mixed investor sentiment [3]

Core Viewpoint - Tian Tan Bio announced that its controlling shareholder, China National Biological Group Corporation, will transfer 18,802,366 shares (0.95% of total shares) to itself without compensation, resulting in China National holding 46.59% of the total shares post-transfer [1] Summary by Sections - **Share Transfer Details** - The transfer involves 18,802,366 shares from Beijing Biological Products Research Institute to China National [1] - After the transfer, China National will directly hold 921,302,854 shares, representing 46.59% of the total share capital [1] - **Ownership Structure Post-Transfer** - Beijing Biological Products Research Institute will no longer hold any shares in the company [1] - China National and its concerted parties will collectively hold 991,120,289 shares, maintaining a total ownership of 50.12% [1]

成大生物回复称，公司产品目前已覆盖30多个国家，主要包括泰国、埃及、印度等 "一带一路" 沿线国 家与地区，相关海外业务正稳步推进。关于您关注的欧盟国家，公司暂无产品出口至该区域。后续若海 外市场拓展有重要进展，公司将按规则及时履行披露。 格隆汇11月25日｜有投资者在互动平台向成大生物提问：了解到公司已出口30多个国家和地区，但是没 有披露具体国家，请问公司近两年(23/24年)是否有出口到欧盟国家呢？ ...